Breast Cancer Diagnostics Market Size, and Share Report Analysis 2032

Breast Cancer Diagnostics Market Size

According to Zion Market Research, the global Breast Cancer Diagnostics Market was worth USD 4.42 Billion in 2023. The market is forecast to reach USD 8.27 Billion by 2032, growing at a compound annual growth rate (CAGR) of 7.2% during the forecast period 2024-2032.

The report offers a comprehensive analysis of the market, highlighting the factors that will determine growth, potential challenges, and opportunities that could emerge in the Breast Cancer Diagnostics Market industry over the next decade.

Request Free Sample

Breast Cancer Diagnostics Market: Overview

Cancer cell detection at the initial stage can minimize the rate of deaths caused due to breast cancer in women. Researchers have studied a large number of breast diagnostics procedures such as mammography, ultrasound, positron emission tomography, computerized tomography, biopsy, and magnetic resonance imaging. Nevertheless, these methods have proved to be very costly as well as time-consuming along with not apt for young females.

Hence, it has become the need of an hour for introducing diagnostic procedures for determining breast cancer tumors or lumps at the initial phase. Investigators are focusing on developing biosensors for detecting breast cancer through the use of various kinds of biomarkers. Apart from using biomarkers & biosensors, researchers are studying microwave imaging system functionalities to use it as a diagnostic tool for breast screening & detecting breast cancer at an early stage in the coming years. According to NCBI, in recent years microwave imaging methods have been prescribed by doctors as a safe & inexpensive alternate tool to mammography for breast cancer diagnosis.  

Request Free Sample

Breast Cancer Diagnostics Market: Growth Drivers

A substantial decrement in breast-cancer-related deaths in countries such as the U.S. from 1975 to 2000 due to constant improvement in breast cancer diagnostic & screening methods will increment the breast cancer diagnostics market size in coming years. Early detection of breast cancer will result in an increase in the survival rates of patients, thereby driving industry trends.  Furthermore, breakthroughs in molecular biology & pharmacology domains for knowing breast cancer and thus facilitating the development of new modes of breast cancer treatments will steer the expansion of the breast cancer diagnostics market in the next few years. With biomarker-based screening techniques such as ELISA, radioimmunoassay, fluoroimmunoassay, and immunohistochemistry catering to the needs of breast cancer diagnostics, the market is anticipated to gain traction in the upcoming years.

Moreover, favorable government schemes facilitating more breast screening & diagnosis for detecting cancer at the initial stage for treatment & curing will create lucrative avenues for the breast cancer diagnostics industry from 2021-2028. The launching of technologically upgraded products such as direct-to-consumer testing products for early diagnosis of cancer in patients will contribute substantially to the size of the breast cancer diagnostics market over the forthcoming years.

Breast Cancer Diagnostics Market: Report Scope

Breast Cancer Diagnostics Market: Regional Landscape

North America To Lead Breast Cancer Diagnostics Market Surge By 2032

The regional market domination over the forecast period can be attributed to a large number of reputed breast cancer diagnostic centers in the U.S. and Canada. Apart from this, the availability of robust diagnostic & screening infrastructure facilities in various countries of North America will pave the way for the growth of the breast cancer diagnostics market in the sub-continent. Growing patient awareness about early diagnosis of breast cancer will further shape market development in the region over the coming decade.

Breast Cancer Diagnostics Market: Competitive Landscape

Key players profiled in the study & influencing market revenue include

• Hologic Inc.
• Danaher Corporation
• QIANGEN N.V.
• Koninklijke Philips N.V.
• F. Hoffmann-La Roche Limited
• Argon Medical Devices. Inc.
• BD.

The global Breast Cancer Diagnostics Market is segmented as follows:

By Type

• Imaging
• Blood Tests
• Genomic Tests
• Biopsy

By Product

• Platform-based
• Instrument-based

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa